Yes. Shingles can affect your eyes, and it is a medical emergency when it does. The varicella-zoster virus reactivates inside a sensory nerve, travels down its fibers, and can inflame the cornea, iris, retina, or optic nerve. Roughly 10 to 20 percent of shingles cases involve the eye, and most of those begin with a blistering rash on one side of the forehead, nose, or eyelid.
The virus behind shingles is the same one that causes chickenpox. After chickenpox resolves, varicella-zoster virus (VZV) does not leave the body. It retreats into clusters of nerve cell bodies beside the spinal cord and brainstem, called dorsal root and trigeminal ganglia, and stays dormant there for decades. Shingles, medically called herpes zoster, happens when that dormant virus wakes up and travels along the nerve toward the skin.
When the awakened nerve is the ophthalmic division of the trigeminal nerve, the skin it supplies is the forehead, upper eyelid, and bridge of the nose. That branch also carries sensation from the eye itself. So the same reactivation event that produces a rash can inflame the surface of the eye, its internal chambers, and the nerve that carries vision signals to the brain. This pattern is called herpes zoster ophthalmicus, or HZO, and it accounts for the large majority of shingles cases that threaten eyesight.
The reason eye involvement is dangerous is not the rash. It is the inflammation and the timing. Antiviral treatment works best within 72 hours of rash onset. Eye complications can also arrive in waves over months, and even years, long after the skin has healed. A person whose rash has faded can still be developing a corneal ulcer or raised pressure inside the eye.
Plain-language version: shingles in the eye is a nerve-driven infection, not just a skin problem, and it needs to be checked quickly even if the skin looks minor.
How the virus reaches the eye
Nerve anatomy explains almost everything about how shingles affects eyes. The trigeminal nerve is the main sensory nerve of the face. It splits into three divisions: the ophthalmic (upper face and eye), the maxillary (cheek and mid-face), and the mandibular (jaw). Only the ophthalmic branch supplies the eye and the skin around it.
When VZV reactivates in the trigeminal ganglion, it travels down the ophthalmic branch's fibers toward the skin. The virus multiplies in skin cells as it goes, which is why the rash follows a band-shaped pattern on one side of the face. But the ophthalmic branch also has fibers that reach the conjunctiva, the cornea, and structures deeper inside the eye. Virus particles and the immune response they trigger can reach those tissues along the same nerve route, or through virus-laden tears and local spread.
The damage comes from two directions. The first is direct viral injury: VZV infects cells in the cornea's outer layer, the iris, and the ciliary body, the ring of tissue that controls the lens and produces fluid inside the eye. The second is immune injury: the body's own inflammatory response to the virus can scar the cornea or inflame blood vessels. In the long term, nerve damage and scarring, rather than active virus, cause most of the lasting vision loss.
A less obvious route is the optic nerve. In some cases VZV reaches the optic nerve directly, or inflammation spreads to it from nearby tissue, producing optic neuritis. That can blur or dim vision without any rash near the eye at first, which is one reason eye symptoms are not always tied to an obvious facial blister.
The skin sign that matters most is Hutchinson's sign: blisters on the tip or side of the nose. That skin is supplied by the nasociliary branch, a sub-branch of the ophthalmic nerve whose other fibers reach the eye. Hutchinson's sign is associated with a higher risk of eye involvement, which is why clinicians look at the nose as closely as the eye.
How often eye involvement happens, and what threatens vision
Quantified context matters here because the numbers frame urgency. Herpes zoster ophthalmicus represents an estimated 10 to 20 percent of all herpes zoster cases. Of those eye cases, a large share develop at least one eye complication, and some patients develop more than one over time.
The eye complications fall into recognizable patterns, and knowing which structures are involved explains the symptoms:
Keratitis: inflammation of the cornea. It can begin as tiny swollen spots on the cornea's surface, called punctate keratitis, and later involve deeper corneal layers. It causes pain, tearing, light sensitivity, and blurred vision. Uveitis: inflammation of the iris and ciliary body. It produces a red, painful eye, sensitivity to light, and often a smaller pupil on the affected side. Scleritis and episcleritis: inflammation of the white outer wall of the eye, causing deep aching pain that can worsen at night. Acute retinal necrosis: a rare but severe infection of the retina, with progressive vision loss that can become permanent. Optic neuritis: inflammation of the optic nerve, producing vision loss and sometimes pain with eye movement. Neurotrophic keratopathy: loss of corneal sensation and healing capacity, which can lead to persistent corneal ulcers, thinning, and perforation.
The counterintuitive detail is that the eye can worsen after the rash heals. VZV-related corneal and inflammatory problems commonly recur. Keratitis and uveitis can flare months after the initial episode, and neurotrophic keratopathy is a late complication driven by nerve loss rather than active infection. This is why follow-up eye exams continue well beyond the rash phase, and why a healed face does not mean the eye is safe.
Timeline: what happens, and when
The time course helps separate early treatment windows from late complications. These intervals describe typical patterns, not guarantees, and individual courses vary.
| Phase | Typical timing | What is happening |
|---|---|---|
| Prodrome | 1 to 5 days before rash | Burning, tingling, or pain in the dermatome; sometimes headache or malaise |
| Active rash and early eye signs | Days 0 to 7 | Blisters appear; keratitis or uveitis can start within the first week |
| Peak inflammation window | Days 7 to 21 | Uveitis, scleritis, and corneal involvement are most likely to show up |
| Early recurrence risk | Weeks to a few months | Corneal and inflammatory flares can recur during recovery |
| Late corneal complications | Months | Neurotrophic keratopathy, persistent ulcers, and scarring can emerge |
| Postherpetic neuralgia | Months to years | Nerve pain persists in some patients after the rash resolves |
| Vision outcome | Variable | Scarring, glaucoma, and nerve damage can leave lasting deficits |
Antiviral therapy is most effective when started within 72 hours of rash onset. That threshold exists because early treatment blunts viral replication before it spreads widely along the nerve and into eye tissues. After that window, antivirals may still be used in severe or eye-involving cases, but the evidence for benefit is strongest early.
Two thresholds are sometimes confused. The 72-hour rule is about starting antiviral treatment. A separate urgency rule applies to the eye: new eye symptoms in a person with facial shingles warrant same-day or next-day evaluation, regardless of how many days have passed since the rash began. Early treatment and early eye evaluation are related but not identical deadlines.
Misconceptions and a professional caveat
Several common beliefs cause people to delay care.
The first misconception is that shingles only affects skin. The rash is the visible part of a nerve infection. Eye structures share the same nerve supply, so eye involvement is a direct consequence of the same event, not a coincidence.
The second is that eye involvement requires a rash near the eye. Most HZO cases do involve the forehead or eyelid, but the eye can be affected even when the external rash is subtle or mainly on the nose. Relying on rash appearance alone can miss corneal or internal inflammation.
The third is that the illness is over when the blisters crust. Corneal and inflammatory complications, especially neurotrophic keratopathy, can appear or worsen after the skin heals. The eye has its own timeline.
The professional caveat is that eye findings can be quiet. Early corneal changes and mild uveitis may produce only light sensitivity or slight blurring. Because the skin rash dominates attention, patients and clinicians both can underweight subtle eye symptoms. A slit-lamp exam by an eye care professional is the reliable way to find these changes; symptoms alone are not a sufficient screen.
When to act: red flags and practical steps
The following signs should prompt urgent eye evaluation rather than a wait-and-see approach:
Blisters on the tip or side of the nose, known as Hutchinson's sign. Any new eye pain, redness, or light sensitivity during or after facial shingles. Blurred or decreased vision in the affected eye, even if mild. A sensation that something is in the eye, or excessive tearing. A smaller pupil on the side with the rash. Eye symptoms that worsen or return after the rash has healed.
Practical steps follow from those red flags. The first is timing: contact a clinician within 72 hours of rash onset for antiviral treatment, and ask specifically about eye evaluation if the rash is on the forehead, eyelid, or nose. The second is to see an eye care professional for a slit-lamp examination when any eye symptom appears; this exam detects corneal and internal inflammation that a general look cannot. The third is to keep follow-up appointments even after the skin clears, because late corneal complications are common.
A further practical point concerns prevention. The recombinant zoster vaccine is recommended by the CDC for adults aged 50 and older, and for adults 19 and older who are immunocompromised. Vaccination reduces the risk of shingles and its complications, including ophthalmic involvement. The vaccine does not treat an active episode, so it belongs in the prevention conversation, not the acute-care conversation.
Plain-language version: if shingles touches your forehead or nose, treat the eye as part of the same emergency, and get it examined even when the skin is the only obvious problem.
Limits of what the evidence shows
Several limits deserve honesty. First, the exact proportion of HZO cases that develop each specific eye complication varies across studies and care settings, so any single percentage should be read as an estimate rather than a fixed rule. Second, much of the evidence on late complications comes from specialty eye clinics, which may overrepresent severe cases. Third, antiviral timing recommendations are based on the strongest evidence for early treatment; the benefit of starting treatment later in eye-involving cases is less certain, and clinical judgment varies.
Vision outcomes are similarly variable. Some patients recover fully, while others have persistent corneal scarring, glaucoma, or nerve-related vision loss. There is no single predictor that captures all of this, and individual prognosis depends on which structures are involved and how quickly care begins.
What the evidence supports clearly is the core message: shingles can affect the eye, the mechanism runs through the ophthalmic nerve, the window for early antiviral treatment is short, and eye complications can appear or recur after the rash fades. Acting on those facts, rather than waiting for the skin to heal, is what protects vision.